The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
CAR T Cells Releasing IL-18 Convert to T-Bethigh FoxO1low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors
Open accessAbstract
Adoptive therapy with chimeric antigen receptor (CAR)-redirected T cells has achieved remarkable efficacy in the treatment of hematopoietic malignancies. However, eradicating large solid tumors in advanced stages of the disease remains challenging. We explored augmentation of the anti-tumor immune reaction by establishing an acute inflammatory reaction. Systematic screening indicates that IL-18 polarizes CAR T cells toward T-bet high FoxO1 low effectors with an acute inflammatory response. CAR T cells engineered with inducible IL-18 release exhibited superior activity against large pancreatic and lung tumors that were refractory to CAR T cells without cytokines. IL-18 CAR T cell treatment was accompanied by an overall change in the immune cell landscape associated with the tumor. More specifically, CD206 − M1 macrophages and NKG2D + NK cells increased in number, whereas Tregs, suppressive CD103 + DCs, and M2 macrophages decreased, suggesting that "iIL18 TRUCKs" can be used to sensitize large solid tumor lesions for successful immune destruction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
O’Rourke, D. M., Nasrallah, M. P., Desai, A., Melenhorst, J. J., Mansfield, K., Morrissette, J. J. D., Martinez-Lage, M., Brem, S., Maloney, E., Shen, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0984 · Cited by 1,803
Broz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.007 · Cited by 1,207
Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004
De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation
Ghoneim, H. E., Fan, Y., Moustaki, A., Abdelsamed, H. A., Dash, P., Dogra, P., Carter, R., Awad, W., Neale, G., Thomas, P. G., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.007 · Cited by 781
TRUCKs: the fourth generation of CARs
Chmielewski, M., & Abken, H. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1046430 · Cited by 738
Self-citationAugmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
Hu, B., Ren, J., Luo, Y., Keith, B., Young, R. M., Scholler, J., Zhao, Y., & June, C. H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.002 · Cited by 506
Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers
Zhang, C., Wang, Z., Yang, Z., Wang, M., Li, S., Li, Y., Zhang, R., Xiong, Z., Wei, Z., Shen, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.010 · Cited by 451
Staron, M. M., Gray, S. M., Marshall, H. D., Parish, I. A., Chen, J. H., Perry, C. J., Cui, G., Li, M. O., & Kaech, S. M. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.013 · Cited by 385
IL-18 Induces PD-1–Dependent Immunosuppression in Cancer
Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Desbois, M., Delahaye, N., Viaud, S., Ryffel, B., Yagita, H., Kaplanski, G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0993 · Cited by 376
Cutting Edge: Priming of NK Cells by IL-18
Chaix, J., Tessmer, M. S., Hoebe, K., Fuséri, N., Ryffel, B., Dalod, M., Alexopoulou, L., Beutler, B., Brossay, L., Vivier, E., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.1627 · Cited by 374
Rao, R. R., Li, Q., Bupp, M. R. G., & Shrikant, P. A. (2012) · Immunity · doi:10.1016/j.immuni.2012.01.015 · Cited by 293
Feng, K., Guo, Y., Dai, H., Wang, Y., Li, X., Jia, H., & Han, W. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-5023-8 · Cited by 290
T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion
Utzschneider, D. T., Legat, A., Fuertes Marraco, S. A., Carrié, L., Luescher, I., Speiser, D. E., & Zehn, D. (2013) · Nature Immunology · doi:10.1038/ni.2606 · Cited by 283
Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy
Maus, M. V., & June, C. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1433 · Cited by 265
Interleukin‐18 acts as an angiogenesis and tumor suppressor
CAO, R., FARNEBO, J., KURIMOTO, M., & CAO, Y. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.15.2195 · Cited by 211
T-bet and Eomesodermin Are Required for T Cell-Mediated Antitumor Immune Responses
Zhu, Y., Ju, S., Chen, E., Dai, S., Li, C., Morel, P., Liu, L., Zhang, X., & Lu, B. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000749 · Cited by 189
The paradox of pro-inflammatory cytokines in cancer
Dinarello, C. A. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9000-8 · Cited by 170
Human Tc1 and Tc2/Tc0 CD8 T-cell clones display distinct cell surface and functional phenotypes
Vukmanovic-Stejic, M., Vyas, B., Gorak-Stolinska, P., Noble, A., & Kemeny, D. M. (2000) · Blood · doi:10.1182/blood.v95.1.231 · Cited by 161
Wong, J. L., Berk, E., Edwards, R. P., & Kaliński, P. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4366 · Cited by 157
Chmielewski, M. M., Hahn, O., Rappl, G., Nowak, M. A., Schmidt‐Wolf, I. G. H., Hombach, A. A., & Abken, H. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.037 · Cited by 154
Self-citationThe structural basis for receptor recognition of human interleukin-18
Tsutsumi, N., Kimura, T., Arita, K., Ariyoshi, M., Ohnishi, H., Yamamoto, T. S., Zuo, X., Maenaka, K., Park, E. Y., Kondo, N., et al. (2014) · Nature Communications · doi:10.1038/ncomms6340 · Cited by 149
Zhang, L., Tschumi, B. O., Lopez-Mejia, I. C., Oberle, S. G., Meyer, M., Samson, G., Rüegg, M. A., Hall, M. N., Fajas, L., Zehn, D., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.095 · Cited by 134
Development of CD8+ Effector T Cells Is Differentially Regulated by IL-18 and IL-12
Okamoto, I., Kohno, K., Tanimoto, T., Ikegami, H., & Kurimoto, M. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.6.3202 · Cited by 124
Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression
Vidal‐Vanaclocha, F., Mendoza, L., Tellería, N., Salado, C., Valcárcel, M., Gallot, N., Carrascal, T., Egilegor, E., Beaskoetxea, J., & Dinarello, C. A. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9013-3 · Cited by 122
The growing world of CAR T cell trials: a systematic review
Holzinger, A., Barden, M., & Abken, H. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1895-5 · Cited by 122
Self-citationAugmentation of Immune Checkpoint Cancer Immunotherapy with IL18
Ma, Z., Li, W., Yoshiya, S., Xu, Y., Hata, M., El‐Darawish, Y., Markova, T., Yamanishi, K., Yamanishi, H., Tahara, H., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1655 · Cited by 99
Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy
Śledzińska, A., Menger, L., Bergerhoff, K. F., Peggs, K. S., & Quezada, S. A. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.008 · Cited by 95
Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity
Pasero, C., & Olive, D. (2013) · Immunology Letters · doi:10.1016/j.imlet.2013.01.008 · Cited by 70
Markowitz, G. J., Yang, P., Fu, J., Michelotti, G. A., Chen, R., Sui, J., Yang, B., Qin, W., Zhang, Z., Wang, F., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1548 · Cited by 56
Novel immunotherapies for hematologic malignancies
Nelson, M. H., & Paulos, C. M. (2014) · Immunological Reviews · doi:10.1111/imr.12245 · Cited by 53
Guo, X., Zheng, L., Jiang, J., Zhao, Y., Wang, X., Shen, M., Zhu, F., Tian, R., Shi, C., Xu, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1144 · Cited by 49
Abken, H. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.115 · Cited by 38
Self-citationClinical significance of serum interleukin-18 (IL-18) levels in patients with gastric cancer
Taş, F., Yasasever, C. T., Karabulut, S., et al. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.12.040 · Cited by 36
Enhanced expression of interleukin-18 in serum and pancreas of patients with chronic pancreatitis
Schneider, A. T. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i40.6507 · Cited by 33
Schwartzberg, L. S., Peták, I., Stewart, C. F., Turner, P. K., Ashley, J., Tillman, D. M., Douglas, L., Tan, M., Billups, C. A., Mihalik, R., et al. (2002) · PubMed · Cited by 32
Chmielewski, M. M., Rappl, G., Hombach, A. A., & Abken, H. (2012) · Gene Therapy · doi:10.1038/gt.2012.21 · Cited by 26
Self-citationJohn, L. B., Chee, T., Gilham, D. E., & Darcy, P. K. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0345-0_16 · Cited by 2
Cited by
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,472
Martinez, M., & Moon, E. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00128 · Cited by 851
Clinical relevance of tumour-associated macrophages
Pittet, M. J., Michielin, O., & Migliorini, D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00620-6 · Cited by 731
Diverging inflammasome signals in tumorigenesis and potential targeting
Karki, R., & Kanneganti, T.-D. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0123-y · Cited by 641
Engineering CAR-T Cells for Next-Generation Cancer Therapy
Hong, M., Clubb, J. D., & Chen, Y. Y. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.005 · Cited by 639
Metadata
- Authors
- Chmielewski, M., & Abken, H.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 21
- Issue
- 11
- Pages
- 3205-3219
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2773065484
- Cited by
- 429
- References
- 37
- FWCI
- 12.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.